TickerFacts.

Company research / OPK

Opko Health, Inc. (OPK)

Build a valuation ↗↓ Download CSV

SEC name OPKO HEALTH, INC. · CIK 0000944809 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Opko Health, Inc. reported revenue of $606.88M. Revenue fell 14.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $587.90M.

Key ratios (year ended 2025-12-31)

33.9%
Gross margin
-19.3%
Operating margin
-37.2%
Net margin
-17.8%
Return on year-end equity
-14.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-15

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$587.90M$606.88M$713.14M$863.50M$1.00B$1.77B$1.44B$901.93M$990.27M$966.01M$1.12B
Cost of Revenue$348.20M$400.94M$494.63M$545.37M$715.98Mn/an/an/an/an/a$564.10M
Gross Profit$239.69M$205.94M$218.51M$318.13M$288.22Mn/an/an/an/an/a$553.39M
R&D Expense$125.22M$124.03M$105.21M$89.59M$73.89M$76.85M$75.32M$117.87M$125.59M$126.44M$113.87M
Operating Income-$48.25M-$117.41M-$152.06M-$157.02M-$226.25M$18.75M$57.71M-$274.05M-$171.20M-$276.44M-$96.55M
Depreciation & Amortization$89.72M$91.63M$98.18M$105.30M$108.66M$78.72M$85.36M$93.81M$97.34M$102.09M$96.58M
EBITDA$41.47M-$25.78M-$53.89M-$51.72M-$117.60M$97.47M$143.08M-$180.25M-$73.85M-$174.35M$25.0K
Net Income-$72.89M-$225.68M-$53.22M-$188.86M-$328.40M-$30.14M$30.59M-$314.93M-$153.04M-$305.25M-$48.36M
EPS (Diluted)n/a-$0.30-$0.08-$0.25-$0.46-$0.05$0.05-$0.53-$0.27-$0.55-$0.10
Total Assets$1.83B$1.93B$2.20B$2.01B$2.17B$2.40B$2.47B$2.31B$2.45B$2.59B$2.77B
Total Liabilities$645.29M$663.99M$834.76M$622.48M$605.61M$714.59M$801.51M$694.51M$659.78M$746.33M$674.81M
Long-Term Debt$349.05M$343.97M$437.20M$50.6K$256.25M$205.27M$251.21M$270.30Mn/an/an/a
Shareholders' Equity$1.18B$1.27B$1.37B$1.39B$1.56B$1.69B$1.67B$1.61B$1.79B$1.84Bn/a
Cash & Equivalents$300.76M$364.41M$426.58M$95.88M$153.19M$134.71M$72.21M$85.45M$96.47M$91.50M$168.73M
Operating Cash Flow-$123.38M-$178.54M-$183.49M-$28.20M-$95.19M$38.34M$39.48M-$172.52M-$109.14M-$92.08M$32.05M
Capital Expenditures$10.64M$12.28M$25.01M$16.27M$24.58M$32.16M$33.68M$12.74M$27.86M$46.52M$18.55M
Free Cash Flow-$134.02M-$190.82M-$208.50M-$44.47M-$119.77M$6.18M$5.79M-$185.26M-$137.00M-$138.60M$13.50M
Share Repurchases$46.57M$47.04M$90.22M$0$0n/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a751.13M694.02M751.77M719.06M648.08M640.66M595.45M563.14M559.16M555.61M
EPS (Basic)n/a-$0.30-$0.08-$0.25-$0.46-$0.05$0.05-$0.53-$0.27-$0.55-$0.09

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView